BD (Becton, Dickinson and Company) is set to invest more than $35m in its Columbus, Nebraska facility to expand the manufacturing of prefilled flush syringes.
The company will also add around 50 new jobs to support the production amid rising demand from hospitals and health systems.
The investment will facilitate the introduction of new BD PosiFlush Prefilled Flush Syringe production lines, as well as support product innovation and operational efficiencies.
The expansion will enable BD to produce hundreds of millions of additional units annually.
Prefilled flush devices, such as PosiFlush Prefilled Flush Syringes, are integral to catheter care and maintenance in hospitals, preventing complications and supporting patient care.
PosiFlush Syringes are produced via a fully automated, hands-free process to minimise contamination risks.
Each syringe undergoes a stringent, multi-step inspection process to uphold high-quality standards for patients and providers.
Over the last three years, BD has invested over $80m to expand PosiFlush capacity, boosting US production by more than 750 million units, including a 10% increase this year.
The Columbus facility, operational for over 75 years, is the largest manufacturer of prefilled flush devices in the US.
BD medication delivery solutions worldwide president Eric Borin said: “BD PosiFlush Syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications.
“Our latest investments boost U.S. production capacity and reinforce our commitment to a reliable supply for health care providers and the patients they serve.”
Earlier this year, BD revealed plans to invest $2.5bn in US manufacturing capacity over the next five years.
The investment includes over $40m to expand capacity for syringes, needles, and IV catheters, essential products for clinical care.
BD operates more than 30 manufacturing and distribution facilities across 17 states and Puerto Rico, employing over 10,000 people.
Recently, BD agreed to combine its biosciences and diagnostic solutions business with Waters in a transaction valued at around $17.5bn.
The merger, structured as a Reverse Morris Trust to maximise tax efficiency, aims to establish a leading entity in the life sciences and diagnostics field.
